Literature DB >> 29574659

The 5α-Reductase Inhibitor Finasteride Exerts Neuroprotection Against Ischemic Brain Injury in Aged Male Rats.

Motoki Tanaka1, Takunori Ogaeri2, Mikhail Samsonov3, Masahiro Sokabe4.   

Abstract

Progesterone (P4) exerts potent neuroprotection both in young and aged animal models of stroke. The neuroprotection is likely to be mediated by allopregnanolone (ALLO) metabolized from P4 by 5α-reductase, since the neuroprotection is attenuated by the 5α-reductase inhibitor finasteride, which was done only with young animals though. Thus, we do not know the contribution of ALLO to the P4-induced neuroprotection in aged animals. We examined effects of finasteride on the P4-induced neuroprotection in aged (16-18-month-old) male rats subjected to transient focal cerebral ischemia. Transient focal cerebral ischemia was induced by left middle cerebral artery occlusion (MCAO) and occlusion of the bilateral common carotid arteries. MCAO rats were given an 8 mg/kg P4 6 h after MCAO followed by the same treatment once a day for successive 3 days. Finasteride, a 5α-reductase inhibitor, at 20 mg/kg was intraperitoneally injected 30 min prior to the P4-injections. P4 markedly reduced neuronal damage 72 h after MCAO, and the P4-induced neuroprotection was apparently suppressed by finasteride in the aged animals. However, post-ischemic administration of finasteride alone (20 mg/kg) significantly prevented neuronal damage and the impairment of Rotarod performance after MCAO in aged male rats, but not in young ones. The androgen receptor antagonist flutamide markedly suppressed the neuroprotection of finasteride in the cerebral cortex, but not in the striatum, suggesting the androgen receptor-dependent mechanism of the finasteride-induced neuroprotection in the cerebral cortex. Our findings suggested, for the first time, the potential of finasteride as a therapeutic agent in post-ischemic treatment of strokes in aged population.

Entities:  

Keywords:  5α-reductase inhibitor; Finasteride; Middle cerebral artery occlusion; Progesterone; Stroke

Mesh:

Substances:

Year:  2018        PMID: 29574659     DOI: 10.1007/s12975-018-0624-0

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  64 in total

1.  The effect of finasteride in men with benign prostatic hyperplasia. 1992.

Authors:  Gleen J Gormley; Elizabeth Stoner; Reginald C Bruskewitz; Julianne Imperato-McGinley; Patrick C Walsh; John D McConnell; Gerald L Andriole; Jack Geller; Bruce R Bracken; Joyce S Tenover; E Darracott Vaughan; Frances Pappas; Alice Taylor; Bruce Binkowitz; Jennifer Ng
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

2.  Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia.

Authors:  Mai T Dang; Fumiaki Yokoi; Kevin St P McNaught; Toni-Ann Jengelley; Tehone Jackson; Jianyong Li; Yuqing Li
Journal:  Exp Neurol       Date:  2005-10-20       Impact factor: 5.330

3.  Inhibition of rat alpha-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition.

Authors:  B Azzolina; K Ellsworth; S Andersson; W Geissler; H G Bull; G S Harris
Journal:  J Steroid Biochem Mol Biol       Date:  1997-04       Impact factor: 4.292

4.  Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.

Authors:  J L Roberts; V Fiedler; J Imperato-McGinley; D Whiting; E Olsen; J Shupack; D Stough; R DeVillez; R Rietschel; R Savin; W Bergfeld; J Swinehart; T Funicella; M Hordinsky; N Lowe; I Katz; A Lucky; L Drake; V H Price; D Weiss; E Whitmore; L Millikan; S Muller; C Gencheff
Journal:  J Am Acad Dermatol       Date:  1999-10       Impact factor: 11.527

5.  Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry.

Authors:  Nandavar Shobha; Alastair M Buchan; Michael D Hill
Journal:  Cerebrovasc Dis       Date:  2010-12-21       Impact factor: 2.762

6.  Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies.

Authors:  Gregory W Albers; Larry B Goldstein; David C Hess; Lawrence R Wechsler; Karen L Furie; Philip B Gorelick; Patty Hurn; David S Liebeskind; Raul G Nogueira; Jeffrey L Saver
Journal:  Stroke       Date:  2011-08-18       Impact factor: 7.914

7.  Allopregnanolone activates GABA(A) receptor/Cl(-) channels in a multiphasic manner in embryonic rat hippocampal neurons.

Authors:  Qi-Ying Liu; Yoong H Chang; Anne E Schaffner; Susan V Smith; Jeffery L Barker
Journal:  J Neurophysiol       Date:  2002-09       Impact factor: 2.714

8.  Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion.

Authors:  Iqbal Sayeed; Qingmin Guo; Stuart W Hoffman; Donald G Stein
Journal:  Ann Emerg Med       Date:  2006-02-21       Impact factor: 5.721

9.  Dose-dependent effects of androgens on outcome after focal cerebral ischemia in adult male mice.

Authors:  Masayoshi Uchida; Julie M Palmateer; Paco S Herson; A Courtney DeVries; Jian Cheng; Patricia D Hurn
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-13       Impact factor: 6.200

10.  TTC, fluoro-Jade B and NeuN staining confirm evolving phases of infarction induced by middle cerebral artery occlusion.

Authors:  Fudong Liu; Dorothy P Schafer; Louise D McCullough
Journal:  J Neurosci Methods       Date:  2009-01-09       Impact factor: 2.390

View more
  4 in total

1.  Rh-CSF1 attenuates neuroinflammation via the CSF1R/PLCG2/PKCε pathway in a rat model of neonatal HIE.

Authors:  Xiao Hu; Shirong Li; Desislava Met Doycheva; Lei Huang; Cameron Lenahan; Rui Liu; Juan Huang; Shucai Xie; Jiping Tang; Gang Zuo; John H Zhang
Journal:  J Neuroinflammation       Date:  2020-06-10       Impact factor: 8.322

2.  IL-20R Activation via rIL-19 Enhances Hematoma Resolution through the IL-20R1/ERK/Nrf2 Pathway in an Experimental GMH Rat Pup Model.

Authors:  Shengpeng Liu; Jerry J Flores; Bo Li; Shuixiang Deng; Gang Zuo; Jun Peng; Jiping Tang; John H Zhang
Journal:  Oxid Med Cell Longev       Date:  2021-01-19       Impact factor: 6.543

3.  DKK3 attenuates JNK and AP-1 induced inflammation via Kremen-1 and DVL-1 in mice following intracerebral hemorrhage.

Authors:  Yang Xu; Derek Nowrangi; Hui Liang; Tian Wang; Lingyan Yu; Tai Lu; Zhengyang Lu; John H Zhang; Benyan Luo; Jiping Tang
Journal:  J Neuroinflammation       Date:  2020-04-24       Impact factor: 8.322

4.  Longxuetongluo Capsule protects against cerebral ischemia/reperfusion injury through endoplasmic reticulum stress and MAPK-mediated mechanisms.

Authors:  Bo Pan; Jing Sun; Ziyu Liu; Lingxiao Wang; Huixia Huo; Yunfang Zhao; Pengfei Tu; Wei Xiao; Jiao Zheng; Jun Li
Journal:  J Adv Res       Date:  2021-02-09       Impact factor: 10.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.